Ursodeoxycholic acid in cholestasis: Linking action mechanisms to therapeutic applications

Clinical Science

Volumn 121, Issue 12, 2011, Pages 523-544

  Roma, Marcelo G ^a   Toledo, Flavia D ^a   Boaglio, Andrea C ^a   Basiglio, Cecilia L ^a   Crocenzi, Fernando A ^a   Sánchez Pozzi, Enrique J ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Bile acid; Cell death; Cholestasis; Hepatocellular transporter; Immunomodulation; ursodeoxycholic acid (UCDA)

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BILE ACID; CHENODEOXYCHOLIC ACID; CYTOKINE; DEATH RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN BAX; PROTEIN BCL 2; TAURINE; URSODEOXYCHOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BILE DUCT; BILE FLOW; CELL DEATH; CELL MEMBRANE; CHINESE MEDICINE; CHOLESTASIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; JAUNDICE; LIVER CELL; LIVER DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS; TRADITIONAL MEDICINE; URINARY EXCRETION; VIRUS HEPATITIS;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; BILE CANALICULI; CHOLAGOGUES AND CHOLERETICS; CHOLESTASIS; HUMANS; IMMUNOLOGIC FACTORS; MITOCHONDRIA, LIVER; PROTO-ONCOGENE PROTEINS C-BCL-2; URSODEOXYCHOLIC ACID;

EID: 80052401062     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110184     Document Type: Review

References (225)

1. Leuschner, U., Fischer, H., Kurtz, W., Guldutuna, S., Hubner, K., Hellstern, A., Gatzen, M. and Leuschner, M. (1989) Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 97, 1268-1274
2. Scholmerich, J., Becher, M. S., Schmidt, K., Schubert, R., Kremer, B., Feldhaus, S. and Gerok, W. (1984) Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties: studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 4, 661-666
3. Perez, M. J. and Briz, O. (2009) Bile-acid-induced cell injury and protection. World J. Gastroenterol. 15, 1677-1689
4. Hofmann, A. F. (1994) Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand. J. Gastroenterol. Suppl. 204, 1-15
5. Poupon, R. E., Chretien, Y., Poupon, R. and Paumgartner, G. (1993) Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 17, 599-604
6. Beuers, U., Spengler, U., Zwiebel, F. M., Pauletzki, J., Fischer, S. and Paumgartner, G. (1992) Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15, 603-608
7. Rudolph, G., Endele, R., Senn, M. and Stiehl, A. (1993) Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 17, 1028-1032
8. Sinakos, E., Marschall, H. U., Kowdley, K. V., Befeler, A., Keach, J. and Lindor, K. (2010) Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 52, 197-203
9. Mazzella, G., Parini, P., Bazzoli, F., Villanova, N., Festi, D., Aldini, R., Roda, A., Cipolla, A., Polimeni, C., Tonelli, D. and Roda, E. (1993) Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig. Dis. Sci. 38, 896-902
10. Brites, D. (2002) Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann. Hepatol. 1, 20-28
11. Tribe, R. M., Dann, A. T., Kenyon, A. P., Seed, P., Shennan, A. H. and Mallet, A. (2010) Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am. J. Gastroenterol. 105, 585-595
12. Fickert, P., Fuchsbichler, A., Marschall, H. U., Wagner, M., Zollner, G., Krause, R., Zatloukal, K., Jaeschke, H., Denk, H. and Trauner, M. (2006) Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am. J. Pathol. 168, 410-422
13. Lindor, K. D., Kowdley, K. V., Luketic, V. A., Harrison, M. E., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J. et al. (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50, 808-814
14. Lazaridis, K. N., Gores, G. J. and Lindor, K. D. (2001) Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J. Hepatol. 35, 134-146
15. Setchell, K. D., Rodrigues, C. M., Clerici, C., Solinas, A., Morelli, A., Gartung, C. and Boyer, J. (1997) Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112, 226-235
16. Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. and Houwen, R. H. (2010) Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52, 258-271
17. Fischer, S., Beuers, U., Spengler, U., Zwiebel, F. M. and Koebe, H. G. (1996) Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin. Chim. Acta 251, 173-186
18. Hofmann, A. F. (1999) Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14, 24-29
19. Benz, C., Angermuller, S., Tox, U., Kloters-Plachky, P., Riedel, H. D., Sauer, P., Stremmel,W. and Stiehl, A. (1998) Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J. Hepatol. 28, 99-106
20. Maher, J. J. (2004) What doesn't kill you makes you stronger: how hepatocytes survive prolonged cholestasis. Hepatology 39, 1141-1143
21. Maillette de Buy, W. L. and Beuers, U. (2010) Bile salts and cholestasis. Dig. Liver Dis. 42, 409-418
22. Guicciardi, M. E. and Gores, G. J. (2002) Ursodeoxy-cholic acid cytoprotection: dancing with death receptors and survival pathways. Hepatology 35, 971-973
23. Schoemaker, M. H., Conde de la, R. L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L. and Moshage, H. (2004) Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39, 1563-1573
24. Rolo, A. P., Palmeira, C. M., Holy, J. M. and Wallace, K. B. (2004) Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: the switch between apoptosis and necrosis. Toxicol. Sci. 79, 196-204
25. Benz, C., Angermuller, S., Otto, G., Sauer, P., Stremmel, W. and Stiehl, A. (2000) Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur. J. Clin. Invest. 30, 203-209
26. Neuman, M. G., Cameron, R. G., Haber, J. A., Katz, G. G. and Blendis, L. M. (2002) An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. Liver 22, 235-244
27. Koga, H., Sakisaka, S., Ohishi, M., Sata, M. and Tanikawa, K. (1997) Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25, 1077-1084
28. Lleo, A., Bowlus, C. L., Yang, G. X., Invernizzi, P., Podda, M., Van de Water, J., Ansari, A. A., Coppel, R. L., Worman, H. J., Gores, G. J. and Gershwin, M. E. (2010) Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52, 987-998
29. Sokol, R. J., Straka, M. S., Dahl, R., Devereaux, M. W., Yerushalmi, B., Gumpricht, E., Elkins, N. and Everson, G. (2001) Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr. Res. 49, 519-531
30. Yerushalmi, B., Dahl, R., Devereaux, M. W., Gumpricht, E. and Sokol, R. J. (2001) Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 33, 616-626
31. Rolo, A. P., Oliveira, P. J., Moreno, A. J. and Palmeira, C. M. (2001) Chenodeoxycholate is a potent inducer of the permeability transition pore in rat liver mitochondria. Biosci. Rep. 21, 73-80
32. Sokol, R. J., Dahl, R., Devereaux, M. W., Yerushalmi, B., Kobak, G. E. and Gumpricht, E. (2005) Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 41, 235-243
33. Krahenbuhl, S., Talos, C., Fischer, S. and Reichen, J. (1994) Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 19, 471-479
34. Spivey, J. R., Bronk, S. F. and Gores, G. J. (1993) Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J. Clin. Invest. 92, 17-24
35. Reinehr, R., Becker, S., Keitel, V., Eberle, A., Grether-Beck, S. and Haussinger, D. (2005) Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 129, 2009-2031
36. Botla, R., Spivey, J. R., Aguilar,H., Bronk, S. F. and Gores, G. J. (1995) Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J. Pharmacol. Exp. Ther. 272, 930-938
37. Rodrigues, C. M., Fan, G.,Wong, P. Y., Kren, B. T. and Steer, C. J. (1998) Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol. Med. 4, 165-178
38. Lapenna, D., Ciofani, G., Festi, D., Neri, M., Pierdomenico, S. D., Giamberardino, M. A. and Cuccurullo, F. (2002) Antioxidant properties of ursodeoxycholic acid. Biochem. Pharmacol. 64, 1661-1667
39. Okada, K., Shoda, J., Taguchi, K., Maher, J. M., Ishizaki, K., Inoue, Y., Ohtsuki, M., Goto, N., Takeda, K., Utsunomiya, H. et al. (2008) Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G735-G747
40. Kawata, K., Kobayashi, Y., Souda, K., Kawamura, K., Sumiyoshi, S., Takahashi, Y., Noritake, H., Watanabe, S., Suehiro, T. and Nakamura, H. (2010) Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. Antioxid. Redox. Signaling 13, 259-268
41. Mitsuyoshi, H., Nakashima, T., Sumida, Y., Yoh, T., Nakajima, Y., Ishikawa, H., Inaba, K., Sakamoto, Y., Okanoue, T. and Kashima, K. (1999) Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem. Biophys. Res. Commun. 263, 537-542
42. Serviddio, G., Pereda, J., Pallardo, F. V., Carretero, J., Borras, C., Cutrin, J., Vendemiale, G., Poli, G., Vina, J. and Sastre, J. (2004) Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39, 711-720
43. Bernstein, C., Payne, C. M., Bernstein, H. and Garewal, H. (2002) Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate. Pharmacology 65, 2-9
44. Arisawa, S., Ishida, K., Kameyama, N., Ueyama, J., Hattori, A., Tatsumi, Y., Hayashi, H., Yano, M., Hayashi, K., Katano, Y. et al. (2009) Ursodeoxycholic acid induces glutathione synthesis through activation of PI3K/Akt pathway in HepG2 cells. Biochem. Pharmacol. 77, 858-866
45. Lemasters, J. J., Qian, T., He, L., Kim, J. S., Elmore, S. P., Cascio, W. E. and Brenner, D. A. (2002) Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid. Redox. Signaling 4, 769-781
46. Rodrigues, C. M., Ma, X., Linehan-Stieers, C., Fan, G., Kren, B. T. and Steer, C. J. (1999) Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death. Differ. 6, 842-854
47. Brunelle, J. K. and Letai, A. (2009) Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci. 122, 437-441
48. Shaulian, E. and Karin, M. (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, E131-E136
49. Bernt, C., Vennegeerts, T., Beuers, U. and Rust, C. (2006) The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem. Biophys. Res. Commun. 340, 800-806
50. Pusl, T., Vennegeerts, T.,Wimmer, R., Denk, G. U., Beuers, U. and Rust, C. (2008) Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem. Biophys. Res. Commun. 367, 208-212
51. Qiao, L., Yacoub, A., Studer, E., Gupta, S., Pei, X. Y., Grant, S., Hylemon, P. B. and Dent, P. (2002) Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 35, 779-789
52. Sola, S., Aranha, M. M., Steer, C. J. and Rodrigues, C. M. (2007) Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr. Issues Mol. Biol. 9, 123-138
53. Miller, S. D., Greene, C. M., McLean, C., Lawless, M.W., Taggart, C. C., O'Neill, S. J. and McElvaney, N. G. (2007) Tauroursodeoxycholic acid inhibits apoptosis induced by Z α-1 antitrypsin via inhibition of Bad. Hepatology 46, 496-503
54. Amaral, J. D., Castro, R. E., Sola, S., Steer, C. J. and Rodrigues, C. M. (2007) p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J. Biol. Chem. 282, 34250-34259
55. Amaral, J. D., Castro, R. E., Sola, S., Steer, C. J. and Rodrigues, C. M. (2010) Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53. Biochem. Biophys. Res. Commun. 400, 649-654
56. Liu, H., Qin, C. Y., Han, G. Q., Xu, H.W., Meng, M. and Yang, Z. (2007) Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J. Gastroenterol. 13, 1652-1658
57. Tarao, K., Fujiyama, S., Ohkawa, S., Miyakawa, K., Tamai, S., Hirokawa, S., Masaki, T. and Tanaka, K. (2005) Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol. Biomarkers Prev. 14, 164-169
58. Utanohara, S., Tsuji, M., Momma, S., Morio, Y. and Oguchi, K. (2005) The effect of ursodeoxycholic acid on glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicology 214, 77-86
59. 2+ and activates phosphorylase a in isolated hepatocytes. Am. J. Physiol 264, G243-G251
60. Fracchia, M., Setchell, K. D., Crosignani, A., Podda, M., O'Connell, N., Ferraris, R., Hofmann, A. F. and Galatola, G. (1996) Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid. Clin. Chim. Acta 248, 175-185
61. Marchesini, G., Bugianesi, E., Bianchi, G., Fabbri, A., Marchi, E., Zoli, M. and Pisi, E. (1992) Effect of S-adenosyl-l-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clin. Nutr. 11, 303-308
62. Chawla, R. K., Lewis, F. W., Kutner, M. H., Bate, D. M., Roy, R. G. and Rudman, D. (1984) Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 87, 770-776
63. Correia, J. P., Areias, E., Meneses, L. and Tiago, E. (1977) Bile salts secretion in cirrhosis. Acta Hepatogastroenterol. 24, 15-19
64. Adams, L. A., Angulo, P., Petz, J., Keach, J. and Lindor, K. D. (2010) A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol. Int. 4, 628-633
65. Leuschner, U. F., Lindenthal, B., Herrmann, G., Arnold, J. C., Rossle, M., Cordes, H. J., Zeuzem, S., Hein, J. and Berg, T. (2010) High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52, 472-479
66. Tinmouth, J., Lee, M., Wanless, I. R., Tsui, F. W., Inman, R. and Heathcote, E. J. (2002) Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 22, 228-234
67. Syn, W. K., Choi, S. S. and Diehl, A. M. (2009) Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin. Liver Dis. 13, 565-580
68. Sodeman, T., Bronk, S. F., Roberts, P. J., Miyoshi, H. and Gores, G. J. (2000) Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am. J. Physiol. Gastrointest. Liver Physiol 278, G992-G999
69. Higuchi, H., Bronk, S. F., Takikawa, Y., Werneburg, N., Takimoto, R., El-Deiry, W. and Gores, G. J. (2001) The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J. Biol. Chem. 276, 38610-38618
70. Li, S., Zhao, Y., He, X., Kim, T. H., Kuharsky, D. K., Rabinowich, H., Chen, J., Du, C. and Yin, X. M. (2002) Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J. Biol. Chem. 277, 26912-26920
71. Azzaroli, F., Mehal, W., Soroka, C. J., Wang, L., Lee, J., Crispe, N. and Boyer, J. L. (2002) Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 36, 49-54
72. Malhi, H. and Kaufman, R. J. (2011) Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795-809
73. Faitova, J., Krekac, D., Hrstka, R. and Vojtesek, B. (2006) Endoplasmic reticulum stress and apoptosis. Cell. Mol. Biol. Lett. 11, 488-505
74. Lamkanfi, M., Kalai, M. and Vandenabeele, P. (2004) Caspase-12: an overview. Cell Death. Differ. 11, 365-368
75. Tsuchiya, S., Tsuji, M., Morio, Y. and Oguchi, K. (2006) Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicol. Lett. 166, 140-149
76. Xie, Q., Khaoustov, V. I., Chung, C. C., Sohn, J., Krishnan, B., Lewis, D. E. and Yoffe, B. (2002) Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 36, 592-601
77. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Gorgun, C. Z. and Hotamisligil, G. S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140
78. Balmer, M. L., Siegrist, K., Zimmermann, A. and Dufour, J. F. (2009) Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int. 29, 1184-1188
79. Eichhorst, S. T. (2005) Modulation of apoptosis as a target for liver disease. Expert Opin. Ther. Targets 9, 83-99
80. Chen, W., Liu, J. and Gluud, C. (2007) Bile acids for viral hepatitis. Cochrane Database Syst. Rev. 2007, CD003181, doi: 10.1002/14651858.CD003181.pub2
81. Malhotra, J. D. and Kaufman, R. J. (2007) Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox. Signaling 9, 2277-2293
82. Kapoor, A. and Sanyal, A. J. (2009) Endoplasmic reticulum stress and the unfolded protein response. Clin. Liver Dis. 13, 581-590
83. Lukivskaya, O., Lis, R., Egorov, A., Naruta, E., Tauschel, H. D. and Buko, V. U. (2004) The protective effect of ursodeoxycholic acid in alloxan-induced diabetes. Cell. Biochem. Funct. 22, 97-103
84. Ramalho, R. M., Viana, R. J., Low, W. C., Steer, C. J. and Rodrigues, C. M. (2008) Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol. Med. 14, 54-62
85. Duan, W. M., Rodrigues, C. M., Zhao, L. R., Steer, C. J. and Low, W. C. (2002) Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant. 11, 195-205
86. Keene, C. D., Rodrigues, C. M., Eich, T., Chhabra, M. S., Steer, C. J. and Low, W. C. (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 99, 10671-10676
87. Rodrigues, C. M., Fan, G., Ma, X., Kren, B. T. and Steer, C. J. (1998) A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 101, 2790-2799
88. Colell, A., Coll, O., Garcia-Ruiz, C., Paris, R., Tiribelli, C., Kaplowitz, N. and Fernandez-Checa, J. C. (2001) Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology 34, 964-971
89. Kremer, A. E., Rust, C., Eichhorn, P., Beuers, U. and Holdenrieder, S. (2009) Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Rev. Mol. Diagn. 9, 139-156
90. Harada, K., Ozaki, S., Gershwin, M. E. and Nakanuma, Y. (1997) Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 26, 1399-1405
91. Hirschfield, G. M., Heathcote, E. J. and Gershwin, M. E. (2010) Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 139, 1481-1496
92. Sola, S., Amaral, J. D., Castro, R. E., Ramalho, R. M., Borralho, P. M., Kren, B. T., Tanaka, H., Steer, C. J. and Rodrigues, C. M. (2005) Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes. Hepatology 42, 925-934
93. Miura, T., Ouchida, R., Yoshikawa, N., Okamoto, K., Makino, Y., Nakamura, T., Morimoto, C., Makino, I. and Tanaka, H. (2001) Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 276, 47371-47378
94. Schoemaker, M. H., Gommans, W. M., Conde de la Rosa, L., Homan, M., Klok, P., Trautwein, C., van Goor, H., Poelstra, K., Haisma, H. J., Jansen, P. L. and Moshage, H. (2003) Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-κ B activation. J. Hepatol. 39, 153-161
95. Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M. et al. (2008) Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc. Natl. Acad. Sci. U.S.A. 105, 10895-10900
96. Lukivskaya, O., Zavodnik, L., Knas, M. and Buko, V. (2006) Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51, 54-59
97. Uraz, S., Tahan, V., Aygun, C., Eren, F., Unluguzel, G., Yuksel, M., Senturk, O., Avsar, E., Haklar, G., Celikel, C., Hulagu, S. and Tozun, N. (2008) Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig. Dis. Sci. 53, 1071-1077
98. Soza, A., Riquelme, F., Alvarez, M., Duarte, I., Glasinovic, J. C. and Arrese, M. (1999) Hepatotoxicity by amoxicillin/clavulanic acid: case report. Rev. Med. Chil. 127, 1487-1491
99. Poupon, R. and Serfaty, L. (2007) Ursodeoxycholic acid in chronic hepatitis C. Gut 56, 1652-1653
100. Kiso, S., Kawata, S., Imai, Y., Tamura, S., Inui, Y., Ito, N. and Matsuzawa, Y. (1996) Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyltranspeptidase levels. J. Gastroenterol. 31, 75-80
101. Rodrigues, C. M., Sola, S., Nan, Z., Castro, R. E., Ribeiro, P. S., Low, W. C. and Steer, C. J. (2003) Taurourso-deoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. U.S.A. 100, 6087-6092
102. Sola, S., Castro, R. E., Laires, P. A., Steer, C. J. and Rodrigues, C. M. (2003) Tauroursodeoxycholic acid prevents amyloid-β peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol. Med. 9, 226-234
103. Rodrigues, C. M., Stieers, C. L., Keene, C. D., Ma, X., Kren, B. T., Low, W. C. and Steer, C. J. (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J. Neurochem. 75, 2368-2379
104. Fickert, P., Trauner, M., Fuchsbichler, A., Zollner, G., Wagner, M., Marschall, H. U., Zatloukal, K. and Denk, H. (2005) Oncosis represents the main type of cell death in mouse models of cholestasis. J. Hepatol. 42, 378-385
105. Wang, R., Lam, P., Liu, L., Forrest, D., Yousef, I. M., Mignault, D., Phillips, M. J. and Ling, V. (2003) Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatology 38, 1489-1499
106. Smit, J. J., Schinkel, A. H., Oude Elferink, R. P., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A., Ottenhoff, R., van der Lugt, N. M., van Roon, M. A. et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451-462
107. Nakanuma, Y. (1993) Necroinflammatory changes in hepatic lobules in primary biliary cirrhosis with less well-defined cholestatic changes. Hum. Pathol. 24, 378-383
108. Degott, C., Zafrani, E. S., Callard, P., Balkau, B., Poupon, R. E. and Poupon, R. (1999) Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29, 1007-1012
109. Aadland, E., Schrumpf, E., Fausa, O., Elgjo, K., Heilo, A., Aakhus, T. and Gjone, E. (1987) Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22, 655-664
110. Evason, K., Bove, K. E., Finegold, M. J., Knisely, A. S., Rhee, S., Rosenthal, P., Miethke, A. G., Karpen, S. J., Ferrell, L. D. and Kim, G. E. (2011) Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies. Am. J. Surg. Pathol. 35, 687-696
111. Heuman, D. M., Pandak, W. M., Hylemon, P. B. and Vlahcevic, Z. R. (1991) Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 14, 920-926
112. Ohiwa, T., Katagiri, K., Hoshino, M., Hayakawa, T. and Nakai, T. (1993) Tauroursodeoxycholate and tauro-β-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology 17, 470-476
113. Basiglio, C. L., Mottino, A. D. and Roma, M. G. (2010) Tauroursodeoxycholate counteracts hepatocellular lysis induced by tensioactive bile salts by preventing plasma membrane-micelle transition. Chem.-Biol. Interact. 188, 386-392
114. Heuman, D. M., Mills, A. S., McCall, J., Hylemon, P. B., Pandak, W. M. and Vlahcevic, Z. R. (1991) Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 100, 203-211
115. Sokol, R. J., Devereaux, M., Khandwala, R. and O'Brien, K. (1993) Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 17, 869-881
116. Sokol, R. J., Winklhofer-Roob, B. M., Devereaux, M. W. and McKim, Jr, J. M. (1995) Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 109, 1249-1256
117. Sokol, R. J., McKim, Jr, J. M., Goff, M. C., Ruyle, S. Z., Devereaux, M. W., Han, D., Packer, L. and Everson, G. (1998) Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114, 164-174
118. Borgognone, M., Perez, L. M., Basiglio, C. L., Ochoa, J. E. and Roma, M. G. (2005) Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes. Toxicol. Sci. 83, 114-125
119. Billington, D., Evans, C. E., Godfrey, P. P. and Coleman, R. (1980) Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem. J. 188, 321-327
120. Woudenberg-Vrenken, T. E., Buist-Homan, M., Conde de la, R. L., Faber, K. N. and Moshage, H. (2010) Anti-oxidants do not prevent bile acid-induced cell death in rat hepatocytes. Liver Int. 30, 1511-1521
121. Heuman, D. M. and Bajaj, R. (1994) Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 106, 1333-1341
122. Guldutuna, S., Deisinger, B., Weiss, A., Freisleben, H. J., Zimmer, G., Sipos, P. and Leuschner, U. (1997) Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim. Biophys. Acta 1326, 265-274
123. Zhou, Y., Doyen, R. and Lichtenberger, L. M. (2009) The role of membrane cholesterol in determining bile acid cytotoxicity and cytoprotection of ursodeoxycholic acid. Biochim. Biophys. Acta 1788, 507-513
124. Heuman, D. M., Bajaj, R. S. and Lin, Q. (1996) Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J. Lipid Res. 37, 562-573
125. Basiglio, C. L., Sanchez Pozzi, E. J., Mottino, A. D. and Roma, M. G. (2009) Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem.-Biol. Interact. 179, 297-303
126. Rosmorduc, O. and Poupon, R. (2007) Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J. Rare Dis. 2, 29
127. Benedetti, A., Alvaro, D., Bassotti, C., Gigliozzi, A., Ferretti, G., La Rosa, T., Di Sario, A., Baiocchi, L. and Jezequel, A. M. (1997) Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 26, 9-21
128. Nakanuma, Y., Tsuneyama, K. and Harada, K. (2001) Pathology and pathogenesis of intrahepatic bile duct loss. J. Hepatobiliary Pancreat. Surg. 8, 303-315
129. Que, F. G., Phan, V. A., Phan, V. H., LaRusso, N. F. and Gores, G. J. (1999) GUDC inhibits cytochrome c release from human cholangiocyte mitochondria. J. Surg. Res. 83, 100-105
130. Rodriguez-Ortigosa, C. M., Banales, J. M., Olivas, I., Uriarte, I., Marin, J. J., Corrales, F. J., Medina, J. F. and Prieto, J. (2010) Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology 52, 667-677
131. Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Pojer, C., Zenz, R., Lammert, F., Stieger, B., Meier, P. J., Zatloukal, K. et al. (2001) Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121, 170-183
132. Zollner, G., Fickert, P., Fuchsbichler, A., Silbert, D., Wagner, M., Arbeiter, S., Gonzalez, F. J., Marschall, H. U., Zatloukal, K., Denk, H. and Trauner, M. (2003) Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 39, 480-488
133. Zollner, G., Wagner, M., Moustafa, T., Fickert, P., Silbert, D., Gumhold, J., Fuchsbichler, A., Halilbasic, E., Denk, H., Marschall, H. U. and Trauner, M. (2006) Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G923-G932
134. Salvioli, G., Lugli, R., Pradelli, J. M., Frignani, A. and Boccalletti, V. (1988) Urinary excretion of bile acids during acute administration in man. Eur. J. Clin. Invest. 18, 22-28
135. Takikawa, H., Beppu, T. and Seyama, Y. (1984) Urinary concentrations of bile acid glucuronides and sulfates in hepatobiliary diseases. Gastroenterol. Jpn 19, 104-109
136. Matern, S., Matern, H., Farthmann, E. H. and Gerok, W. (1984) Hepatic and extrahepatic glucuronidation of bile acids in man. Characterization of bile acid uridine 5′-diphosphate-glucuronosyltransferase in hepatic, renal, and intestinal microsomes. J. Clin. Invest. 74, 402-410
137. Huang, J., Bathena, S. P., Tong, J., Roth, M., Hagenbuch, B. and Alnouti, Y. (2010) Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica 40, 184-194
138. Schuetz, E. G., Strom, S., Yasuda, K., Lecureur, V., Assem, M., Brimer, C., Lamba, J., Kim, R. B., Ramachandran, V., Komoroski, B. J. et al. (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276, 39411-39418
139. Wagner, M., Zollner, G. and Trauner, M. (2010) Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 30, 160-177
140. Stahl, S., Davies, M. R., Cook, D. I. and Graham, M. J. (2008) Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38, 725-777
141. Wagner, M., Fickert, P., Zollner, G., Fuchsbichler, A., Silbert, D., Tsybrovskyy, O., Zatloukal, K., Guo, G. L., Schuetz, J. D., Gonzalez, F. J. et al. (2003) Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125, 825-838
142. Geier, A., Wagner, M., Dietrich, C. G. and Trauner, M. (2007) Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773, 283-308
143. Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Weiglein, A. H., Lammert, F., Marschall, H. U., Tsybrovskyy, O., Zatloukal, K., Denk, H. and Trauner, M. (2002) Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123, 1238-1251
144. Marschall, H. U., Wagner, M., Zollner, G., Fickert, P., Diczfalusy, U., Gumhold, J., Silbert, D., Fuchsbichler, A., Benthin, L., Grundstrom, R. et al. (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129, 476-485
145. Dilger, K., Denk, A., Heeg, M. H. and Beuers, U. (2005) No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41, 595-602
146. Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Marschall, H. U., Zatloukal, K., Denk, H. and Trauner, M. (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38, 717-727
147. Berg, P. A., Klein, R. and Rocken, M. (1997) Cytokines in primary biliary cirrhosis. Semin. Liver Dis. 17, 115-123
148. Al-Hathlol, K., Al-Madani, A., Al-Saif, S., Abulaimoun, B., Al-Tawil, K. and El-Demerdash, A. (2006) Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med. J. 47, 147-151
149. Chen, C. Y., Tsao, P. N., Chen, H. L., Chou, H. C., Hsieh, W. S. and Chang, M. H. (2004) Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J. Pediatr. 145, 317-321
150. Kadayifci, A., Savas, M. C., Arslan, S. and Gullu, I. H. (1997) Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B. J. Clin. Gastroenterol. 24, 125-126
151. Smith, L. A., Ignacio, J. R., Winesett, M. P., Kaiser, G. C., Lacson, A. G., Gilbert-Barness, E., Gonzalez-Peralta, R. P. and Wilsey, Jr, M. J. (2005) Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 41, 469-473
152. Agca, E., Akcay, A. and Simsek, H. (2004) Ursodeoxycholic acid for terbinafine-induced toxic hepatitis. Ann. Pharmacother. 38, 1088-1089
153. Jacquemin, E., Hermans, D., Myara, A., Habes, D., Debray, D., Hadchouel, M., Sokal, E. M. and Bernard, O. (1997) Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25, 519-523
154. Nathwani, R. A. and Kaplowitz, N. (2006) Drug hepatotoxicity. Clin. Liver Dis. 10, 207-217
155. Palma, J., Reyes, H., Ribalta, J., Hernandez, I., Sandoval, L., Almuna, R., Liepins, J., Lira, F., Sedano, M., Silva, O. et al. (1997) Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27, 1022-1028
156. Trauner, M., Arrese, M., Soroka, C. J., Ananthanarayanan, M., Koeppel, T. A., Schlosser, S. F., Suchy, F. J., Keppler, D. and Boyer, J. L. (1997) The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113, 255-264
157. Micheline, D., Emmanuel, J. and Serge, E. (2002) Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J. Pediatr. Gastroenterol. Nutr. 35, 185-191
158. Lee, J. M., Trauner, M., Soroka, C. J., Stieger, B., Meier, P. J. and Boyer, J. L. (2000) Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118, 163-172
159. Crocenzi, F. A., D'Andrea, V., Catania, V. A., Luquita, M. G., Pellegrino, J. M., Ochoa, J. E., Mottino, A. D. and Sanchez Pozzi, E. J. (2005) Prevention of Mrp2 activity impairment in ethinylestradiol-induced cholestasis by ursodeoxycholate in the rat. Drug Metab. Dispos. 33, 888-891
160. Crocenzi, F. A., Pellegrino, J. M., Catania, V. A., Luquita, M. G., Roma, M. G., Mottino, A. D. and Sãnchez Pozzi, E. J. (2006) Galactosamine prevents ethinylestracliolinduced cholestasis. Drug Metab. Dispos. 34, 993-997
161. Corpechot, C., Carrat, F., Bahr, A., Chretien, Y., Poupon, R. E. and Poupon, R. (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128, 297-303
162. Mohanty, M. K., Gupta, S. D. and Bhatnagar, V. (2010) Surgical outcome in relation to duct size at the porta hepatis and the use of cholagogues in patients with biliary atresia. Trop. Gastroenterol. 31, 184-189
163. Glaser, S. S. and Alpini, G. (2009) Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis. Hepatology 49, 1795-1797
164. Renner, E. L., Lake, J. R., Cragoe, Jr, E. J., Van Dyke, R. W. and Scharschmidt, B. F. (1988) Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+ -H+ exchange inhibitors. Am. J. Physiol. 254, G232-G241
165. Knyrim, K., Vakil, N., Pfab, R. and Classen, M. (1989) The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man. Hepatology 10, 134-142
166. Van Nieuwkerk, C. M., Elferink, R. P., Groen, A. K., Ottenhoff, R., Tytgat, G. N., Dingemans, K. P., Van Den BerghWeerman, M. A. and Offerhaus, G. J. (1996) Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111, 165-171
167. Fickert, P., Wagner, M., Marschall, H. U., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., Zatloukal, K., Liu, J., Waalkes, M. P., Cover, C. et al. (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465-481
168. Hofmann, A. F., Zakko, S. F., Lira, M., Clerici, C., Hagey, L. R., Lambert, K. K., Steinbach, J. H., Schteingart, C. D., Olinga, P. and Groothuis, G. M. (2005) Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42, 1391-1398
169. vit-Spraul, A., Gonzales, E., Baussan, C. and Jacquemin, E. (2010) The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin. Liver Dis. 30, 134-146
170. Puglielli, L., Amigo, L., Arrese, M., Nunez, L., Rigotti, A., Garrido, J., Gonzalez, S., Mingrone, G., Greco, A. V., Accatino, L. et al. (1994) Protective role of biliary cholesterol and phospholipid lamellae against bile acid-induced cell damage. Gastroenterology 107, 244-254
171. Prieto, J., Garcia, N., Marti-Climent, J. M., Penuelas, I., Richter, J. A. and Medina, J. F. (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117, 167-172
172. Herrmann, U., Dockter, G. and Lammert, F. (2010) Cystic fibrosis-associated liver disease. Best Pract. Res. Clin. Gastroenterol. 24, 585-592
173. Prieto, J., Qian, C., Garcia, N., Diez, J. and Medina, J. F. (1993) Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 105, 572-578
174. Arenas, F., Hervias, I., Uriz, M., Joplin, R., Prieto, J. and Medina, J. F. (2008) Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J. Clin. Invest. 118, 695-709
175. Nathanson, M. H., Burgstahler, A. D., Masyuk, A. and LaRusso, N. F. (2001) Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem. J. 358, 1-5
176. Fiorotto, R., Spirli, C., Fabris, L., Cadamuro, M., Okolicsanyi, L. and Strazzabosco, M. (2007) Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 133, 1603-1613
177. Alpini, G., Baiocchi, L., Glaser, S., Ueno, Y., Marzioni, M., Francis, H., Phinizy, J. L., Angelico, M. and Lesage, G. (2002) Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKCα. Hepatology 35, 1041-1052
178. Mottino, A. D., Cao, J., Veggi, L. M., Crocenzi, F. A., Roma, M. G. and Vore, M. (2002) Altered localization and activity of canalicular Mrp2 in estradiol-17β-d-glucuronide-induced cholestasis. Hepatology 35, 1409-1419
179. Mottino, A. D., Veggi, L. M., Wood, M., Roman, J. M. and Vore, M. (2003) Biliary secretion of glutathione in estradiol 17β-d-glucuronide-induced cholestasis. J. Pharmacol. Exp. Ther. 307, 306-313
180. Crocenzi, F. A., Mottino, A. D., Sanchez Pozzi, E. J., Pellegrino, J. M., Rodríguez Garay, E. A., Milkiewicz, P., Vore, M., Coleman, R. and Roma, M. G. (2003) Impaired localisation and transport function of canalicular Bsep in taurolithocholate-induced cholestasis in the rat. Gut 52, 1170-1177
181. Paulusma, C. C., Kothe, M. J., Bakker, C. T., Bosma, P. J., van, B., I, van Marle, J., Bolder, U., Tytgat, G. N. and Oude Elferink, R. P. (2000) Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31, 684-693
182. Shoda, J., Kano, M., Oda, K., Kamiya, J., Nimura, Y., Suzuki, H., Sugiyama, Y., Miyazaki, H., Todoroki, T., Stengelin, S. et al. (2001) The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 96, 3368-3378
183. Kojima, H., Sakurai, S., Uemura, M., Kitamura, K., Kanno, H., Nakai, Y. and Fukui, H. (2008) Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases. J. Gastroenterol. Hepatol. 23, e120-e128
184. Keitel, V., Vogt, C., Haussinger, D. and Kubitz, R. (2006) Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131, 624-629
185. Kojima, H., Nies, A. T., Konig, J., Hagmann, W., Spring, H., Uemura, M., Fukui, H. and Keppler, D. (2003) Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J. Hepatol. 39, 693-702
186. Watanabe, N., Takashimizu, S., Kojima, S., Kagawa, T., Nishizaki, Y., Mine, T. and Matsuzaki, S. (2007) Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol. Res. 37, 598-607
187. MAPK activation and translocation of the bile salt export pump in rats. Gastroenterology 121, 407-419
188. Schliess, F., Kurz, A. K., vom, D. S. and Haussinger, D. (1997) Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 113, 1306-1314
189. Haussinger, D., Kurz, A. K., Wettstein, M., Graf, D., vom, D. S. and Schliess, F. (2003) Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis. Gastroenterology 124, 1476-1487
190. Kurz, A. K., Block, C., Graf, D., Dahl, S. V., Schliess, F. and Haussinger, D. (2000) Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver. Biochem. J. 350, 207-213
191. Kubitz, R., Sutfels, G., Kuhlkamp, T., Kolling, R. and Haussinger, D. (2004) Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 126, 541-553
192. Dombrowski, F., Stieger, B. and Beuers, U. (2006) Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab. Invest. 86, 166-174
193. Beuers, U., Bilzer, M., Chittattu, A., Kullak-Ublick, G. A., Keppler, D., Paumgartner, G. and Dombrowski, F. (2001) Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33, 1206-1216
194. Denk, G. U., Hohenester, S., Wimmer, R., Bohland, C., Rust, C. and Beuers, U. (2008) Role of mitogen-activated protein kinases in tauroursodeoxycholic acid-induced bile formation in cholestatic rat liver. Hepatol. Res. 38, 717-726
195. Wimmer, R., Hohenester, S., Pusl, T., Denk, G. U., Rust, C. and Beuers, U. (2008) Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKCα-/PKA-dependent mechanism in rat liver. Gut 57, 1448-1454
196. Innes, G. K., Nagafuchi, Y., Fuller, B. J. and Hobbs, K. E. (1988) Increased expression of major histocompatibility antigens in the liver as a result of cholestasis. Transplantation 45, 749-752
197. Ballardini, G., Mirakian, R., Bianchi, F. B., Pisi, E., Doniach, D. and Bottazzo, G. F. (1984) Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet ii, 1009-1013
198. Hillaire, S., Boucher, E., Calmus, Y., Gane, P., Ballet, F., Franco, D., Moukthar, M. and Poupon, R. (1994) Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 107, 781-788
199. Corpechot, C., Carrat, F., Bonnand, A. M., Poupon, R. E. and Poupon, R. (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32, 1196-1199
200. Tay, J., Tinmouth, A., Fergusson, D., Huebsch, L. and Allan, D. S. (2007) Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 13, 206-217
201. Barnes, D., Talenti, D., Cammell, G., Goormastic, M., Farquhar, L., Henderson, M., Vogt, D., Mayes, J., Westveer, M. K. and Carey, W. (1997) A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 26, 853-857
202. Martinez, O. M., Villanueva, J. C., Gershwin, M. E. and Krams, S. M. (1995) Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 21, 113-119
203. Calmus, Y., Guechot, J., Podevin, P., Bonnefis, M. T., Giboudeau, J. and Poupon, R. (1992) Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-α production by monocytes. Hepatology 16, 719-723
204. Yoshikawa, M., Tsujii, T., Matsumura, K., Yamao, J., Matsumura, Y., Kubo, R., Fukui, H. and Ishizaka, S. (1992) Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16, 358-364
205. Lacaille, F. and Paradis, K. (1993) The immunos-uppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 18, 165-172
206. Hanada, S., Harada, M., Koga, H., Kawaguchi, T., Taniguchi, E., Kumashiro, R., Ueno, T., Ueno, Y., Ishii, M., Sakisaka, S. and Sata, M. (2003) Tumor necrosis factor-α and interferon-γ directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int. 23, 3-11
207. Keane, R. M., Gadacz, T. R., Munster, A. M., Birmingham, W. and Winchurch, R. A. (1984) Impairment of human lymphocyte function by bile salts. Surgery 95, 439-443
208. Bergamini, A., Dini, L., Baiocchi, L., Cappannoli, L., Falasca, L., Bolacchi, F., Capozzi, M., Faggioli, E., Nistri, A., Salanitro, A. et al. (1997) Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 25, 927-933
209. Neuman, M., Angulo, P., Malkiewicz, I., Jorgensen, R., Shear, N., Dickson, E. R., Haber, J., Katz, G. and Lindor, K. (2002) Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 17, 196-202
210. Ishizaki, K., Iwaki, T., Kinoshita, S., Koyama, M., Fukunari, A., Tanaka, H., Tsurufuji, M., Sakata, K., Maeda, Y., Imada, T. and Chiba, K. (2008) Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-α and macrophage inflammatory protein-2 production. Eur. J. Pharmacol. 578, 57-64
211. Fernandes, A., Vaz, A. R., Falcao, A. S., Silva, R. F., Brito, M. A. and Brites, D. (2007) Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin. J. Neuropathol. Exp. Neurol. 66, 789-798
212. van Milligen de Wit, A. W., Kuiper, H., Camoglio, L., van Bracht, J., Jones, E. A., Tytgat, G. N. and van Deventer, S. J. (1999) Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur. J. Gastroenterol. Hepatol. 11, 129-136
213. Crescenzi, E., Pacifico, F., Lavorgna, A., De Palma, R., D'Aiuto, E., Palumbo, G., Formisano, S. and Leonardi, A. (2011) NF-κB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells. Oncogene 30, 2707-2717
214. Shah, S. A., Volkov, Y., Arfin, Q., bdel-Latif, M. M. and Kelleher, D. (2006) Ursodeoxycholic acid inhibits interleukin 1 β and deoxycholic acid-induced activation of NF-κB and AP-1 in human colon cancer cells. Int. J. Cancer 118, 532-539
215. Joo, S. S., Won, T. J. and Lee, D. I. (2004) Potential role of ursodeoxycholic acid in suppression of nuclear factor κB in microglial cell line (BV-2). Arch. Pharm. Res. 27, 954-960
216. Serfaty, L., Bissonnette, M. and Poupon, R. (2010) Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol. Clin. Biol. 34, 516-522
217. Poo, J. L., Feldmann, G., Erlinger, S., Braillon, A., Gaudin, C., Dumont, M. and Lebrec, D. (1992) Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 102, 1752-1759
218. Calmus, Y., Gane, P., Rouger, P. and Poupon, R. (1990) Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11, 12-15
219. Terasaki, S., Nakanuma, Y., Ogino, H., Unoura, M. and Kobayashi, K. (1991) Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am. J. Gastroenterol. 86, 1194-1199
220. Tanaka, H. and Makino, I. (1992) Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 188, 942-948
221. Celada, A., McKercher, S. and Maki, R. A. (1993) Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein. J. Exp. Med. 177, 691-698
222. Tanaka, H., Makino, Y., Miura, T., Hirano, F., Okamoto, K., Komura, K., Sato, Y. and Makino, I. (1996) Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-γ -induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J. Immunol. 156, 1601-1608
223. Saeki, R., Ogino, H., Kaneko, S., Unoura, M. and Kobayashi, K. (1995) Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-γ production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J. Gastroenterol. 30, 739-744
224. Yokomori, H., Oda, M., Wakabayashi, G., Kitajima, M. and Ishii, H. (2003) Ursodeoxycholic acid therapy attenuated expression of adhesion molecule in primary biliary cirrhosis. Intern. Med. 42, 1259-1261
225. Lim, A. G., Wolfhagen, F. H., Verma, A., van Buuren, H. R., Jazrawi, R. P., Levy, J. H., Northfield, T. C. and Schalm, S.W. (1997) Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur. J. Gastroenterol. Hepatol. 9, 155-161